ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: CML is caused by constitutive tyrosine kinase activity of BCR-ABL fusion protein, and great success has been achieved from developing TKIs to treat this deadly disease in clinical settings [1-5].